Substance / Medication

Etidronate disodium

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

7 trials linked to this intervention

7
Total Trials
1
Recruiting
3
With Results

Research Evidence

Published studies and systematic reviews

Sort:
1,25-dihydroxyvitamin D-mediated hypercalcemia associated with solid organ malignancy: a systematic review.
Charoenngam Nipith, Ponvilawan Ben, Rujirachun Pongprueth et al. · Minerva Endocrinol (Torino) · 2025
PMID: 34581546Meta-Analysis
Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study.
Bassatne Aya, Murad Mohammad H, Piggott Thomas et al. · J Clin Endocrinol Metab · 2023
PMID: 36545699Meta-Analysis
Histological evaluation of symptomatic ossification of the anterior longitudinal ligament treated with etidronate disodium: a case report.
Sugimura Yusuke, Miyakoshi Naohisa, Kasukawa Yuji et al. · J Med Case Rep · 2016
PMID: 27832809Case ReportFull text (PMC)
Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium.
Shiraishi Naoki, Kitamura Kenichiro, Miyoshi Taku et al. · Am J Kidney Dis · 2006
PMID: 16797398Case Report
Pseudogout attack induced during etidronate disodium therapy.
Watanabe Hiroshi, Yamada Sayaka, Anayama Satoshi et al. · Mod Rheumatol · 2006
PMID: 16633934Case Report
Familial fibrodysplasia ossificans progressiva: trial with etidronate disodium.
Dua T, Kabra M, Kalra V · Indian Pediatr · 2001
PMID: 11721075Case Report
Rapid microwave synthesis of N,S-doped carbon quantum dots as a novel turn off-on sensor for label-free determination of copper and etidronate disodium.
El-Malla Samah F, Elshenawy Eman A, Hammad Sherin F et al. · Anal Chim Acta · 2022
PMID: 35168733Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Etidronate disodium (substance)
SNOMED CT
387581008
UMLS CUI
C0037507

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
7
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.